March 1, 2024

Genomics for a Cure – Highlighting the Career of Sreekumar Raghavakaimal The Hype Magazine: Uncovering the Pulse of Urban Culture – From Hip Hop to Hollywood! Explore a diverse range of impactful stories, interviews and editorials covering fashion, gaming, film, MMA, EDM, rock and more! www.thehypemagazine.com – The Hype Magazine The Hype Magazine

Sreekumar Raghavakamal, Ph.D., a stalwart in the scientific field of genomics, knows well the devastating impacts of genetic diseases such as diabetes and cancer. Born and raised in Kerala, India, Raghavakamal’s career choice was anything but spontaneous – between a family history of genetic diseases, the subsequent loss of close relatives and an innate curiosity to bring reason to this misfortune, the boy from Kerala was prepared. act from an early age.

Decades later, his contributions to the scientific community have impacted numerous fields of study, including organic chemistry, genomics, pathophysiology, bioinformatics, and many others. And while most researchers in these fields have their own gripping origin stories, Sreekumar Raghavakamal walks a fine line between the sentimental and the logical.

So what is genomics for healing? Well, that’s what drives Raghavakamal’s passion. And now, his efforts have laid the groundwork for what could save millions of lives in the future. Identifying the origin of many complex, genetic diseases may still be a work in progress, but the advances made by Sreekumar Raghavakamal are a great place to expand.

Profound loss has a way of forcing people out of their comfort zones, and perhaps that is the true origin of Sreekumar Raghavakamal’s efforts.

“Many of my family members are diabetic and/or at high risk for diabetes. My father and a brother died of cancer. It really inspired me to focus on those areas.” – Raghavakamal

Thus, his academic journey began with a bachelor’s degree from the University of Kerala, studying mainly chemistry and physics. A few years later, he completed a master’s degree from the same university, characterized by intense research and an unwavering dedication to scientific rigor. During this time, he strengthened his analytical skills to fully understand various chemical processes.

Raghavakamal’s academic career reached its peak when he received his Ph.D. in organic chemistry from the Indian Institute of Technology, Madras. His doctoral research provided the foundational framework for his future contributions to the scientific community, particularly organic compounds, and what eventually led to his specialization in genomics. He then continued his postdoctoral studies at the University of Wisconsin, Madison, training in Bioorganic Chemistry and Physiology.

Throughout his academic career, Raghavakamal has explored various scientific fields and research interests, with an intensive focus on diabetes, cancer and aging. His interests include the pathophysiological study of liver diseases such as non-alcoholic steatohepatitis (NASH), hepatitis C, and hepatocellular carcinoma (liver cancer), as well as the genetic and proteomic (protein-related) basis for complex genetic diseases.

Raghavakaimal also enjoyed bioinformatics, in which he used and helped develop several bioinformatics programs for genomic and proteomic analysis and studied the molecular mechanisms involved in cell motility and skeletal muscle function.

When asked to share a defining moment in his academic training, Raghavakamal commented, “Scientists used low-throughput assays to understand the molecular causes of these diseases. Then, human genomes were sequenced in 2001. This presented an unprecedented opportunity for doctors and scientists to understand the molecular basis of many diseases, including diabetes and cancer.”

Explaining Raghavakamal’s intensive focus on genomics begins with understanding how the field differs from standard genetics. Rather than focusing on specific, individual genes within a person’s DNA, genomics is instead the study of all of their genes, called the ‘genome’.

Studies describe genomes as an organism’s repository of information and highlight how they specifically relate to the primary means for inheriting the organism’s characteristics. Since genetic diseases such as diabetes and cancer depend heavily on inheritance, exploring the environment in which they develop is essential to understanding how they form and how they can be cured.

“In addition to helping doctors understand what causes each person’s cancer, genomics provides information about how an individual’s cancer may progress and their likely response to treatment.” – Raghavakamal

Raghavakamal states: “A prevalent misconception is that genomics only concerns rare diseases with minimal impact on public health. In fact, genomic programming has profound implications for understanding and treating common diseases like cancer.”

So what is genomic programming, also known as whole genome sequencing? All organisms have a unique genetic code, and once an organism’s base sequence has been established, its entire DNA pattern or fingerprint has been identified.

The power of this laboratory procedure is that it identifies a DNA pattern in a single process, mainly through microarrays (laboratory tools used to detect the expression of thousands of genes simultaneously) and proteomic approaches.

Regarding microarrays and proteomics approaches, Raghavakaimal explains in his Q&A: “Microarrays and proteomics experiments generate a lot of data, and collaborations with bioinformatics and doctors are very important in discovering new biomarkers.”

Biomarkers, which can serve as early health warning signs, are the model for predicting, identifying and treating genetic diseases before they worsen. With this in mind, Raghavakamal intends to expand the scope of biomarkers for genetic diseases to find a cure or, better yet, an inhibitor that completely prevents the disease.

Sreekumar Raghavakamal anticipates a transformative role for artificial intelligence (AI) in shaping the future of genetic disease interventions. When asked what role he believes AI will play in the future of cancer research, he stated, “Ongoing research to support the application of AI to cancer genomics is anticipated to enable early detection of various types of cancer and determination of tumor site of origin. This could transform cancer screening… and improve surveillance strategies for cancer survivors.”

In Raghavakamal’s view, the integration of AI into genomics represents a tremendous shift toward personalized medicine. The synergy between AI technologies and high-throughput analysis tools, such as microarrays and proteomics, speeds up data analysis, helping to identify important genetic networks in diseases. This collaboration accelerates the discovery of biomarkers for early disease detection and improves understanding of disease progression and treatment response.

Raghavakamal envisions a future where the collaborative efforts of researchers, bioinformaticians, and clinicians, guided by AI insights, lead to transformative advances in genetic disease interventions. These efforts have the potential to usher in a new era of precision medicine, offering hope for better outcomes and innovative strategies in the ongoing battle against genetic diseases.

As for Sreekumar Raghavakamalhe hopes his efforts can shed light on the hardships of the past, as a way to honor those he has lost to complex illnesses and those currently suffering.


About the author

Dr. Jerry Doby Editor-in-Chief of The Hype Magazine, Media and SEO Consultant, Journalist, Ph.D., and retired combat vet. 2023 recipient of The President’s Lifetime Achievement Award. Partner of the THM Media Group. Member of the US Department of Arts and Culture, the United States Press Agency and ForbesBLK.


Leave a Reply

Your email address will not be published. Required fields are marked *